Compare Novo Nordisk A/S (NVO) vs State Street Real Estate Select Sector SPDR ETF (XLRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs State Street Real Estate Select Sector SPDR ETF — how do they compare? Novo Nordisk A/S trades at $49.35 (market cap $220.53B), while State Street Real Estate Select Sector SPDR ETF trades at $45.34. The key difference: Novo Nordisk A/S pays a 3.63% dividend while State Street Real Estate Select Sector SPDR ETF pays none, and State Street Real Estate Select Sector SPDR ETF is trading nearer its 52-week high, Novo Nordisk A/S nearer its low. Which is the better fit depends on your goals.
| NVO | XLRE | |
|---|---|---|
Market Cap | $220.53B | — |
Sector | Health | Sector/Thematic |
52-Week High | $71.70 | $45.46 |
52-Week Low | $35.29 | $40.01 |
Enterprise Value | $239.49B | — |
Dividend Yield | 3.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $49.38, down 1.87% amid legal action against Eli Lilly over GLP-1 drug advertising. The stock maintains strong fundamentals with a P/E of 11.91 and robust profitability margins (net income margin 37.2%, ROE 71.4%). Recent quarterly earnings consistently beat expectations, with Q1 2026 EPS of $1.04 surpassing the $0.87 estimate. Technical indicators show a bullish moving average signal while oscillators remain neutral, with key support at $48.
Outlook remains positive given strong earnings momentum and market leadership in GLP-1 drugs, though legal risks and competitive pressures from Eli Lilly pose near-term headwinds. Analyst consensus is bullish (57.9% buy ratings) with projected revenue growth to $327.8B in 2026. Key risks include litigation outcomes and market share competition in the weight-loss drug segment.
XLRE, the Real Estate Select Sector SPDR ETF, trades at $45.23 with a slight 0.42% decline. Technical indicators show a bullish trend with strong moving average support, though RSI suggests potential overbought conditions. The ETF has gained 11% year-to-date, benefiting from REIT sector recovery despite interest rate volatility. Recent news highlights XLRE's low 0.08% expense ratio advantage and steady dividend yield around 3.4%.
Outlook remains cautiously optimistic as REIT fundamentals improve with stable NOI growth and potential M&A activity. Key risks include interest rate sensitivity and inflation pressures. Wall Street sentiment is positive with the sector showing resilience amid broader market volatility, though investors should monitor Fed policy shifts that could impact real estate valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About State Street Real Estate Select Sector SPDR ETF
XLRE tracks the Real Estate Select Sector Index, providing exposure to S&P 500 real estate companies. It focuses on equity REITs across residential, industrial, and healthcare sub-sectors, with top holdings like Welltower, Prologis, and American Tower.
Read more on XLRE →
